Progenics Pharmaceuticals Inc.'s registrational Phase IIb study of its novel radiotherapeutic Azedra (iobenguane I 131) Injection, has hit its primary endpoint, setting the stage for an FDA filing in the next quarter and opening up a new ultra-orphan market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?